NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) today announced that four leading cancer centers are enrolling patients as part of the landmark 1,000-patient study designed to characterize the genetic variation in multiple myeloma. The CoMMpass(SM) Study (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile) will be key in developing and advancing new, targeted treatments for patients and informing treatment approaches.
